Contents, Vol. 74, Supplement 1, 1987

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see ‘Information for Readers and Subscribers’).

© Copyright 1987 by
S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) Printed in Switzerland by Thüen AG Offsetdruck, Pratteln ISBN 3-8055-4626-2

Contents
Introduction
Rafflenbeul, W 1
Development of Mononitrates
Tauchert, M; Jansen, W 3
Isosorbide 5-Mononitrate Pharmacokinetics
Chasseaud, L.F 6
Mechanism of Vasodilation by Nitrates: Role of Cyclic GMP
Kukovetz, W.R.; Holzmann, S.; Romanin, C  12
An Evaluation of the Effects of Isosorbide 5-Mononitrate in Patients with Angina on Effort Using Dynamic Electrocardiography and Echocardiography

Novo, S.; Nardi, E.; Alaimo, G.; Centineo, G.; Licata, G.; Strano, A  20
Dose-Effect Relationship amongst Three Different Sustained-Release Forms of Isosorbide 5-Mononitrate in Patients with Coronary Artery Disease

Kenedi, P.; Gathmann-Lewik, U  29
Antianginal Efficacy and Tolerability of 50 mg Sustained-Release Isosorbide 5-Mononitrate in an Open Twelve-Month Observation Study

Heepe, W.; Gathmann-Lewik, U  34
Influence of Isosorbide 5-Mononitrate 20 mg, Sustained-Release 50 mg and Sustained-Release Nifedipine 20 mg on Ischaemic ST-Segment Changes during Holter Monitoring. A Double-Blind Cross-Over Study in Patients with Spontaneous Angina pectoris von Arnim, T  40
Oral Isosorbide 5-Mononitrate Can Protect from Myocardial Ischemia Induced by Ergonovine Test and by Isometric Effort. Preliminary Results from an Echocardiographic Acute Study in Anginal Patients

Distante, A.; Lombardi, M.; Moscarelli, E.; Morales, M.-A.; L’Abbate, A  46
Changing Ideas in the Treatment of Heart Failure – An Overview

Poole-Wilson, P.A  53
Contents

Isosorbide 5-Mononitrate in the Treatment of Left Ventricular Failure following Acute Myocardial Infarction

Murray, R.G.; Gammage, M.D  58
Controlled Study of the Haemodynamic Effects of Isosorbide 5-Mononitrate in Acute Myocardial Infarction

Foresti, A.; De Martini, M.; Valentini, R.; Massari, F.M.; Lotto, A  60
A Comparison of Intravenous Elantan and Frusenide in Patients with Chronic Cardiac Failure

Hutton, I.; McGhie, A.I.; Martin, W.; Tweddle, A.C  65
Acute and Chronic Use of Isosorbide 5-Mononitrate in Patients with Heart Failure

Stephens, J.D.; Marks, C; Woodings, D.; Vandenbarg, M.J  69
Calcium Channel Blocker and Isosorbide 5-Mononitrate in the Management of Chronic Cardiac Failure

Hutton, I.; McGhie, A.I.; Martin, W.; Tweddle, A.C  72
Nitrates in the Treatment of Heart Failure – Concluding Remarks

Poole-Wilson, P.A  76
Author Index  79
Subject Index  80